Fate Therapeutics (FATE) News Today $1.14 +0.03 (+2.23%) Closing price 07/3/2025 02:25 PM EasternExtended Trading$1.16 +0.02 (+1.75%) As of 07/3/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Research Analysts Offer Predictions for FATE Q2 EarningsJuly 4 at 7:03 AM | marketbeat.comRick Atkinson's 'The Fate of the Day' traces the middle years of the American RevolutionJuly 3 at 6:47 PM | yahoo.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 3 at 1:05 PM | globenewswire.comFate Therapeutics (NASDAQ:FATE) Downgraded to "Sell" Rating by Wall Street ZenJune 28, 2025 | marketbeat.comTMNT: Splintered Fate - Official Xbox Launch TrailerJune 26, 2025 | msn.comBrokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Target Price at $3.83June 24, 2025 | americanbankingnews.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Hold" from BrokeragesJune 21, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Stock Price Crosses Below Two Hundred Day Moving Average - Should You Sell?June 20, 2025 | marketbeat.comFate Therapeutics’ SWOT analysis: promising data boosts stock outlookJune 15, 2025 | investing.comFate Therapeutics, Inc.: Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission ...June 13, 2025 | finanznachrichten.deFate Therapeutics price target lowered to $2.20 by BofA on SLE dataJune 13, 2025 | investing.comFate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025June 13, 2025 | nasdaq.comFate Therapeutics (NASDAQ:FATE) Receives "Hold" Rating from Needham & Company LLCJune 12, 2025 | marketbeat.comFate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 CongressJune 11, 2025 | globenewswire.comBank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)June 11, 2025 | marketbeat.comAnalysts Set Expectations for FATE FY2026 EarningsJune 10, 2025 | marketbeat.comAt Fate’s End, new game from Spiritfarer developers, revealedJune 9, 2025 | msn.comFate Therapeutics appoints new board memberJune 1, 2025 | investing.comFate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of DirectorsMay 30, 2025 | globenewswire.comFate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune DiseasesMay 28, 2025 | insidermonkey.comFate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 CongressMay 28, 2025 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by AnalystsMay 28, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Stock Holdings Trimmed by Woodline Partners LPMay 27, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Decreases Position in Fate Therapeutics, Inc. (NASDAQ:FATE)May 22, 2025 | marketbeat.comVestal Point Capital LP Increases Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)May 21, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Holdings Raised by Tang Capital Management LLCMay 20, 2025 | marketbeat.comSphera Funds Management LTD. Purchases Shares of 397,177 Fate Therapeutics, Inc. (NASDAQ:FATE)May 18, 2025 | marketbeat.comNeedham Remains a Hold on Fate Therapeutics (FATE)May 16, 2025 | theglobeandmail.comBarclays Reaffirms Their Buy Rating on Fate Therapeutics (FATE)May 16, 2025 | theglobeandmail.comFate Therapeutics (FATE) Receives a Hold from WedbushMay 16, 2025 | theglobeandmail.comFate Therapeutics (NASDAQ:FATE) Receives Hold Rating from Needham & Company LLCMay 16, 2025 | marketbeat.comFate Therapeutics First Quarter 2025 Earnings: Beats ExpectationsMay 15, 2025 | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Dimensional Fund Advisors LPMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Lowers Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)May 14, 2025 | marketbeat.comFate Therapeutics Reports First Quarter 2025 Financial Results and Business UpdatesMay 13, 2025 | globenewswire.comFate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy SectorMay 9, 2025 | seekingalpha.comBaker BROS. Advisors LP Grows Position in Fate Therapeutics, Inc. (NASDAQ:FATE)May 6, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by BrokeragesMay 4, 2025 | marketbeat.comFate Therapeutics (FATE) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comMarshall Wace LLP Makes New Investment in Fate Therapeutics, Inc. (NASDAQ:FATE)May 3, 2025 | marketbeat.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comFate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual MeetingApril 29, 2025 | globenewswire.comRecent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past yearApril 27, 2025 | finance.yahoo.com249,800 Shares in Fate Therapeutics, Inc. (NASDAQ:FATE) Acquired by XTX Topco LtdApril 24, 2025 | marketbeat.comWalleye Capital LLC Has $1.79 Million Position in Fate Therapeutics, Inc. (NASDAQ:FATE)April 22, 2025 | marketbeat.comCerity Partners LLC Grows Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)April 20, 2025 | marketbeat.comFate Therapeutics receives RMAT designation from FDA for FT819April 14, 2025 | markets.businessinsider.comFate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays OptimisticApril 14, 2025 | msn.comFate Therapeutics gets RMAT status from FDA for Lupus treatmentApril 14, 2025 | msn.comFate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)April 14, 2025 | globenewswire.com Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Media Mentions By Week FATE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FATE News Sentiment▼0.430.55▲Average Medical News Sentiment FATE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FATE Articles This Week▼34▲FATE Articles Average Week Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tyra Biosciences News Bicara Therapeutics News Kura Oncology News Taysha Gene Therapies News Mind Medicine (MindMed) News Abivax News Valneva News Zevra Therapeutics News Bicycle Therapeutics News Septerna News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FATE) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
